Edwards Lifesciences (NYSE:EW) Price Target Raised to $87.00 at Truist Financial

Edwards Lifesciences (NYSE:EW) had its target price upped by Truist Financial from $82.00 to $87.00 in a research note published on Tuesday,Benzinga reports. They currently have a hold rating on the medical research company’s stock.

A number of other research analysts have also issued reports on EW. Mizuho upped their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Monday, September 22nd. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Finally, Evercore ISI set a $88.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $87.33.

Edwards Lifesciences Trading Up 1.8%

Shares of Edwards Lifesciences stock opened at $82.26 on Tuesday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $64.89 and a 12-month high of $83.25. The firm has a market capitalization of $48.29 billion, a price-to-earnings ratio of 11.84, a PEG ratio of 3.88 and a beta of 1.05. The firm’s 50 day simple moving average is $77.49 and its two-hundred day simple moving average is $76.65.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Pacific Capital Partners Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at about $1,760,000. Czech National Bank increased its position in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares during the last quarter. Mirova US LLC increased its position in shares of Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Edwards Lifesciences by 111.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company’s stock valued at $12,532,000 after acquiring an additional 86,186 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.